{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kluger HM"],"funding":["NCATS NIH HHS","NCI NIH HHS","Society for Immunotherapy of Cancer"],"pagination":["e000398"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7174063"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor as standard of care or in an investigational study. However, because of the kinetics and patterns of response to PD-1/PD-L1 blockade, and the lack of consistency in the clinical definitions of resistance to therapy, the design of clinical trials of new agents and interpretation of results remains an important challenge. To address this unmet need, the Society for Immunotherapy of Cancer convened a multistakeholder taskforce-consisting of experts in cancer immuno"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce."],"pmcid":["PMC7174063"],"funding_grant_id":["P30 CA008748","UL1 TR001863"],"pubmed_authors":["Cha E","Sznol M","Ascierto ML","Papadimitrakopoulou VA","Sullivan RJ","Sharon E","Taube JM","Feltquate DM","Gupta S","Callahan MK","Ferris RL","Le DT","LaVallee TM","Tawbi HA","Kluger HM","Rubin EH","Bowden M","Hubbard-Lucey VM","Humphrey RW","Gulley JL","Chen HX","Drake CG","Postow MA","Zappasodi R","Topalian SL"],"additional_accession":[]},"is_claimable":false,"name":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.","description":"As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor as standard of care or in an investigational study. However, because of the kinetics and patterns of response to PD-1/PD-L1 blockade, and the lack of consistency in the clinical definitions of resistance to therapy, the design of clinical trials of new agents and interpretation of results remains an important challenge. To address this unmet need, the Society for Immunotherapy of Cancer convened a multistakeholder taskforce-consisting of experts in cancer immuno","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2026-07-16T00:07:51.906Z","creation":"2026-07-09T10:25:49.388Z"},"accession":"S-EPMC7174063","cross_references":{"pubmed":["32238470"],"doi":["10.1136/jitc-2019-000398"]}}